Alumis Inc. Common Stock
NASDAQ:ALMSBiotechnology
+$0.21 today
- Market cap
- $568.87M
- Beta
- -0.54
- P/E (TTM)
- -12.2
- EPS (TTM)
- -$1.90
Volume 2.01M
Average 1.31M
ALMS Total Assets
Everything the company owns or controls; equal to total liabilities plus equity.
Alumis Inc. Common StockNASDAQ: ALMS
Total Assets · Q2 FY2026 · quarter ended Jun 2026
Total assets falls 8.2% from a year ago
Total assets stood at $560.62M at the end of Q2 FY2026, down 8.2% from a year earlier and down 16.5% from the prior quarter. Over 3 fiscal years it compounded at +56.2% a year.
Context
- Total assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total assets keeps falling in the next quarterly balance sheet after a -8.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Assets history
USD · from the balance sheet
- Latest · FY2025
- 411.94M USD
- Year-over-year change
- +20.8%
- 3-year CAGR
- +56.2%
| Period | Period end | Total Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 411.94M | +20.8% |
| FY2024 | 2024-12-31 | 340.99M | +280.5% |
| FY2023 | 2023-12-31 | 89.61M | -17.2% |
| FY2022 | 2022-12-31 | 108.17M | — |
Total Assets vs competitors
How ALMS compares with its peers on the latest reported figures
- Peers report in different currencies, so total assets is compared through growth and rates rather than absolute size.
- Its year-over-year change of -8.2% is the 4th highest of 9, against a peer median of -24.9%.
- Over three fiscal years its annual growth of +56.2% compares with a peer median of -15.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR |
|---|---|---|---|---|
ALMSAlumis Inc. Common Stock | Jun 2026 | $560.62M USD | -8.2% | +56.2% |
| Mar 2026 | $504.61M USD | +186.8% | +56.4% | |
| Mar 2026 | $329.68M USD | -21.9% | -15.8% | |
| Mar 2026 | $198.72M USD | +0.3% | -14.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | Sep 2025 | €165.63M EUR | — | — |
ARTVArtiva Biotherapeutics, Inc. | Mar 2026 | $105.96M USD | -44.6% | -0.5% |
| Mar 2026 | $99.89M USD | -27.9% | +51.7% | |
| Mar 2026 | $66.48M USD | -28.7% | -26.5% | |
| Mar 2026 | €48.94M EUR | -43.7% | -18.6% | |
| Dec 2025 | $11.5M USD | +1.9% | -24.3% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
| Peer median (excluding ALMS) | — | -24.9% | -15.0% | |
Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Alumis Inc. Common Stock
NASDAQ:ALMS
Intrinsic Alpha fair value
Locked
Current Price
$4.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.